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Abstract
Background. Galectin-3 is an emerging biomarker in cardiovascular disease. Myocardial galectin-3 is 
involved in the pathology of cardiac fibrosis; however, the role of circulating galectin-3 is not yet established.
Objectives. To assess the relationships between circulating galectin-3, fibrosis and outcomes in dilated 
cardiomyopathy (DCM).
Materials and methods. We included 70 patients (age: 48 ±12.1 years, ejection fraction (EF) 24.4 ±7.4%) 
with new-onset DCM (n = 35, ≤6 months). Galectin-3 and procollagen type I and III (PICP, PINP, PIIICP, and 
PIIINP), transforming growth factor β (TGF-β), connective tissue growth factor (CTGF), osteopontin (OPN), 
matrix metalloproteinases (MMP-2 and -9), and tissue inhibitor (TIMP-1) were determined in serum at baseline 
and after 3 and 12 months. Patients underwent endomyocardial biopsy. The endpoint was a combination 
of death and urgent hospitalization at 12 months.
Results. Galectin-3 did not correlate with biopsy-determined fibrosis. Baseline galectin-3 correlated with 
OPN,, TIMP-1, PIIICP, and MMP-2. In new-onset DCM, galectin-3 levels at baseline were higher than at 3 and 
12 months, whereas in chronic DCM there was no difference. Galectin-3 was a predictor of the endpoint 
(hazard ratio (HR) = 1.115; 95% confidence interval (95% CI) = 1.009–1.231; p < 0.05). The best cut-off 
value was 14.54 ng/mL (area under the curve (AUC) = 0.67). Patients with galectin-3 ≥14.54 ng/mL had 
an increased risk of events (HR = 2.569; 95% CI = 1.098–6.009; p < 0.05).
Conclusions. Circulating galectin-3 is unrelated to fibrosis. Serial measurements of galectin-3 correlated with 
markers of fibrosis, including markers of collagen synthesis and OPN. Circulating galectin-3 was independently 
associated with cardiovascular (CV) outcomes in DCM.
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Background
Fibrosis of  the extracellular matrix (ECM) is a com-
mon pathway in many cardiac diseases leading ultimately 
to the development of heart failure (HF).1 Patients with 
dilated cardiomyopathy (DCM) are particularly predis-
posed to extensive ECM fibrosis, specifically reactive fi-
brosis, which contributes to functional impairment and 
subsequent ventricular arrhythmias.2 The mechanisms 
responsible for ECM fibrosis are incompletely described.
Galectin-3 belongs to the β-galactoside-binding lectin 
family and serves as a matricellular protein which binds 
basic components of ECM, such as collagens, elastin and 
fibronectin.3 In vitro studies have revealed that galectin-3 
is a pivotal protein involved in the development of ECM 
fibrosis, as it stimulates transdifferentiation of fibroblasts 
into highly active myofibroblasts that produce ECM com-
pounds, e.g., collagens and elastin, in excess.4 Additionally, 
galectin-3 is an important component of the renin–angio-
tensin–aldosterone pathway that enhances ECM fibrosis.5 
Thus, the significance of myocardial (in situ) galectin-3 
in ECM fibrosis has been unequivocally proven. However, 
the role of circulating galectin-3 is unclear.
Numerous claims were published that circulating galec-
tin-3 is a marker of cardiac fibrosis.6–8 Upon our review 
of the medical literature, it seems that these assertions 
are premature. In fact, very few studies performed an in-
depth evaluation of the associations between circulating 
galectin-3 and ECM fibrosis in HF.9–11 In those studies, 
cardiac fibrosis was assessed, either invasively (by means 
of endomyocardial biopsy (EMB) followed by a detailed 
laboratory assessment of samples) or non-invasively (with 
magnetic resonance imaging (MRI)). The determination 
of late gadolinium enhancement (LGE) or post-LGE T1 
relaxation time served as surrogates of ECM fibrosis. How-
ever, even in those studies, an association between circu-
lating galectin-3 and ECM fibrosis (assessed with either 
method) was not clearly confirmed.
Objectives
Although a  considerable amount of  work has been 
published on the subject of galectin-3 in cardiomyopathy 
and HF, we have identified knowledge gaps that warrant 
further exploration. The relationship between circulat-
ing galectin-3 and cardiac fibrosis is inconclusive. Thus, 
our study rigorously explores the associations between 
galectin-3 and invasively determined ECM fibrosis (ex-
pressed qualitatively and quantitatively) in a homogenous 
group of DCM patients. Furthermore, the relationship 
between galectin-3 and other serum markers of fibrosis 
(such as markers of collagen synthesis, fibrosis controlling 
factors or metalloproteinases (MMPs)) is generally un-
known. The kinetics of serum galectin-3 in DCM patients 
stratified according to disease duration and fibrosis status 
have not been well described. Finally, we aim to explore 
the association between galectin-3 and survival in HF 




Between July 2014 and October 2015, we enrolled 70 
consecutive DCM patients who fulfilled pre-specified cri-
teria and were willing to participate in the study. Dilated 
cardiomyopathy was diagnosed according to the definition 
of the European Society of Cardiology 2007 guidelines, 
after an exclusion of significant coronary artery disease 
(CAD), primary heart valve disease, congenital heart dis-
ease, and arterial hypertension.12 Based on the duration 
of symptoms, patients were divided into equal groups con-
sisting of 35 subjects with new-onset (group 1, ≤6 months) 
and chronic (group 2, >6 months) DCM. The duration 
of HF symptoms was defined as the time from the onset 
of subjective symptoms (dyspnea on exertion or at rest, par-
oxysmal nocturnal dyspnea, orthopnea, palpitations) and/
or edema to the index hospitalization or ambulatory visit 
in cardiology clinic. Patients with the presence of concomi-
tant non-cardiac diseases, such as bone and joint diseases, 
chronic liver insufficiency, peripheral atherosclerosis, and 
neoplasms affecting collagen metabolism and circulating 
levels of procollagens, were excluded. Each patient’s clinical 
status was re-evaluated, with echocardiography and blood 
sampling repeated at 3 and 12 months (patients’ flowchart 
is presented in Fig. 1). We also evaluated 20 healthy volun-
teers as a control group who underwent blood sampling 
and echocardiography. The study protocol was approved 
by the John Paul II Institutional Review Board and the 
Kraków Medical Chamber Ethics Committee (reference 
No. 134/KBL/OIL/2013). All patients gave a written in-
formed consent prior to inclusion in the study.
Endomyocardial biopsy
Endomyocardial biopsy (EMB) procedures were per-
formed by experienced operators via a femoral or jugular 
vein approach. Long (104 cm), flexible, disposable 7 French 
biopsy forceps with small jaws (Cordis®; Johnson & John-
son Co Inc., Miami Lakes, USA) were used.13 Up to 5 myo-
cardial samples were obtained, which were immediately 
stored in  formalin for light microscopic examination. 
The  presence of  fibrosis was determined qualitatively 
and quantitatively by an experienced pathologist blinded 
to the clinical data. Specimens for fibrosis assessment were 
stained with Masson’s trichrome; fibrotic areas stained 
blue, and normal muscle fibers stained red. Collagen vol-
ume fraction (CVF) was assessed with quantitative mor-
phometry as previously described.14
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Laboratory measurements
Venous blood samples for biomarkers measurements 
were drawn after an overnight fast, typically between 8 
a.m. and 9 a.m. After centrifugation, the supernatant was 
stored at –20°C. The concentration of collagen synthesis 
markers (carboxy- and amino-terminal propeptides of pro-
collagen type I and III (PICP, PINP, PIIICP, and PIIINP)) 
and fibrosis controlling factors (transforming growth 
factor β  (TGF-β) and connective tissue growth factor 
(CTGF), osteopontin (OPN), as well as matrix metallo-
proteinases (MMP-2 and -9) and tissue inhibitor (TIMP-1)) 
were determined in plasma using a commercially available 
enzyme-linked immunosorbent assay (ELISA), as previ-
ously described.15 The levels of galectin-3 were measured 
with ELISA using a commercially available kit (Human 
Galectin-3 ELISA, RAF015R; BioVendor, Brno, Czech 
Republic). The serum samples and galectin-3 standard 
dilutions were added to microwells that were coated with 
anti-galectin-3 antibody. Galectin-3 present in the sample 
or standard was bound to antibodies adsorbed to the mi-
crowells. Following incubation, a wash step was performed 
and the horseradish peroxidase (HRP)-conjugated anti-
galectin-3 antibodies were added binding to galectin-3 
captured by the first antibody. Again following incuba-
tion, unbound HRP-conjugated anti-galectin-3 antibodies 
were removed during a wash step, and a substrate solu-
tion reactive with HRP was added to the wells. A colored 
product was formed in proportion to the amount of galec-
tin-3 present in the sample or standard. The reaction was 
terminated by the addition of acid and absorbance was 
measured at 450 nm. The galectin-3 sample concentration 
was determined based on the standard curve. Baseline, 
3- and 12-month measurements of galectin-3, PICP, PINP, 
PIIICP, PIIINP, TGF-β, CTGF, and OPN were obtained; 
however, for MMP-2, MMP-9 and TIMP-1, only baseline 
measurements were available. Intra-assay and inter-assay 
coefficients of variation were <7%.
Statistical analysis
The data are presented either as mean ± standard devia-
tion (SD), median and interquartile range (IQR), or count 
and percentages. The normality of the distribution of vari-
ables was assessed with a Shapiro–Wilk test. Comparisons 
of clinical parameters between 2 groups were conducted 
with a Mann–Whitney U test, as a lack of normality was 
found. Univariate relationships between galectin-3 and 
serum markers of fibrosis were determined with Spear-
man correlation analysis. Two endpoints were analyzed: 
cardiovascular (CV) death and the combined endpoint that 
was composed of CV death and urgent HF hospitalization 
at 12 months. Survival data were analyzed using the Ka-
plan–Meier method, and compared with the log-rank test. 
To examine the associations of galectin-3 with endpoints 
of interest (unadjusted analyses and analyses adjusted for 
age, duration of disease, CVF, ejection fraction (EF), and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP)) 
Cox proportional hazard analyses were performed. Calcu-
lations for the optimal cut-off values of galectin-3 (in order 
to determine the cut-off values for adverse outcomes) were 
carried out using a receiver operating characteristic (ROC) 
curve. Patients were compared according to a galectin-3 
optimal cut-off value, derived from ROC analysis, with 
the use of a log-rank test. All results were considered statis-
tically significant when the p-value was <0.05. All the anal-
yses were conducted in R software v. 3.3.2 (The R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the study 
population. The majority of patients were male (63; 90%) 
with symptomatic HF (New York Heart Association (NYHA) 
death 
(n = 6; 8.6%) 
study population
at 12-month follow-up
(n = 63; 90%) 
incomplete data 
(n = 1; 1.4%) 
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class 2.49 ±0.7). All patients had severely remodeled left 
ventricle (LV; indexed to BSA left ventricle end-systolic 
(LVES) volume 96.1 ±49 mL/m2 and left ventricle end-
diastolic (LVED) volume 126.8 ±59.8 mL/m2) with signifi-
cantly depressed LV systolic (EF 24.4 ±7.4%) and diastolic 
(E/E’ 20.8 ±11.4) function. Approximately 1/3 (24 (34.3%)) 
of patients had ECM fibrosis diagnosed with EMB. Pa-
tients had significantly increased serum NT-proBNP level 
(3373 ±5428 pg/mL). All patients were on optimal medical 
therapy: β-blockers in 69 (98.6%), angiotensin-converting 
enzyme inhibitors/angiotensin II receptor blockers (ACE-I/
ARB) in 68 (97.1%), mineralocorticoid receptor antagonists 
(MRA) in 66 (94%), and implantable cardiac device with 
or without cardiac resynchronization therapy (ICD ±CRT) 
in 20 (28.6%).
Comparison of baseline, 3- and 12-month 
galectin-3 between DCM patients 
and control group
The control group consisted of 20 healthy subjects that 
were previously characterized.15 Comparison of the base-
line, 3- and 12-month serum galectin-3 values of DCM 
patients with baseline values of 20 control subjects is pre-
sented in Table 2. All measurements were significantly 
higher in DCM patients compared to controls.
Relationships between galectin-3, 
invasively determined ECM fibrosis 
and serum markers of fibrosis
Baseline galectin-3 did not correlate with either qualita-
tive ECM fibrosis assessment (r = –0.13, p = 0.29) or quan-
titative measurement, expressed as  CVF (r  =  –0.12, 
p = 0.58). Baseline galectin-3 correlated with the follow-
ing baseline markers of  fibrosis: OPN (0.27; p < 0.02), 
TIMP-1 (0.23; p  <  0.03), PIIICP (0.27; p  <  0.03), and 
MMP-2 (0.27; p < 0.03). Galectin-3 at 3-month follow-
up correlated with the following 3-month markers: OPN 
(0.37; p < 0.004), PINP (0.27; p < 0.03) and PIIINP (0.34; 
p < 0.006). Galectin-3 at 12-month follow-up correlated 
only with 12-month OPN (0.35; p < 0.005) and PIIICP 
(0.29; p < 0.04).
Kinetics of galectin-3 in new-onset  
and chronic DCM
In patients with new-onset DCM, serum levels of galec-
tin-3 at baseline were significantly higher than galectin-3 
levels at 3-and 12-month follow-up (14.01 ng/mL (11.17–
17.8 ng/mL) compared to 12.42 ng/mL (10.34–14.59 ng/mL) 
compared to 12.32 ng/mL (10.22–15.26 ng/mL), respectively; 
Table 1. Baseline characteristics of the study population
Parameter DCM (n = 70)
Age [years] 48 ±12.1










E/E’ (average sep+years) 20.8 ±11.4
ECM fibrosis [n, %] 24 (34.3%)
PA mean [mm Hg] 23.1 ±10.9
PH [n, %] 27 (39.7%)





β-blocker [n, %] 69 (98.6%)
ACE-I or ARB [n, %] 68 (97.1%)
MRA [n, %] 66 (94%)
Furosemide [n, %] 42 (60%)
CRT-D [n, %] 20 (28.6%)
Data are presented as mean ±SD or n (%); DCM – dilated cardiomyopathy; 
BMI – body mass index; NYHA – New York Heart Association; LBBB – left 
bundle branch block; LVESd – left ventricle end-systolic diameter 
indexed to body surface area; LVEDd – left ventricle end-diastolic 
diameter indexed to body surface area; LVEDd/BSA; EF – ejection fraction; 
E/E’ – ratio of early mitral inflow velocity to early mitral myocardial 
velocity; ECM – extracellular matrix; PA mean – mean pulmonary pressure; 
VO2 peak – peak oxygen uptake; Hb – hemoglobin; hs-CRP – high-
sensitivity C-reactive protein; NT-proBNP – N-terminal pro-B-type 
natriuretic peptide; ACE-I – angiotensin-converting  enzyme inhibitors; 
ARB – angiotensin II receptor blockers; MRA – mineralocorticoid receptor 
antagonists; CRT-D – cardiac resynchronization therapy with cardioverter/
defibrillator.
Table 2. Comparison of serum galectin-3 between DCM patients and control group at baseline, 3 and 12-month follow-up
Parameter DCM (n = 70) Control (n = 20) p-value
Baseline galectin-3 [ng/mL] 14.26 (11.03–17.47) 9.84 (8.6–10.9)  <0.001
3-month galectin-3 [ng/mL] 12.5 (10.22–15.07) 9.84 (8.6–10.9) 0.002
12-month galectin-3 [ng/mL] 13.23 (10.43–16.06) 9.84 (8.6–10.9)  <0.001
Data are presented as median and interquartile range; DCM – dilated cardiomyopathy.
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p < 0.001). Of note, there was no difference between values 
at 3- and 12-month follow-up. In contrast, galectin-3 lev-
els in patients with chronic DCM were similar at baseline 
and at 3 and 12 months (14.54 ng/mL (11.04–16.39 ng/mL) 
compared to 12.66 ng/mL (10.12–16.65 ng/mL) compared 
to 13.74 ng/mL (10.43–16.59 ng/mL), respectively; p = 0.18 
and p = 0.58, respectively). Similarly, there were no differ-
ences between 3- and 12-month follow-up (p = 0.27). The ki-
netics of galectin-3 over the 12-month follow-up are pre-
sented separately for new-onset and chronic DCM groups 
in Fig. 2 and Fig. 3. The kinetics of galectin-3 in new-onset 
DCM are characterized by a decreasing pattern (Fig. 2); 
in chronic DCM, the kinetics of galectin-3 are flat. Com-
parisons of baseline, 3- and 12-month galectin-3 values 
between new-onset and chronic DCM revealed that there 
were no differences between the 2 groups (Table 3, Fig. 4).
Kinetics of galectin-3 in DCM patients  
with and without fibrosis
Galectin-3 serum levels were similar at the index visit, 
3- and 12-month follow-up in patients with ECM fibrosis 
(12.9 ng/mL (10.33–16.18 ng/mL) compared to 12.18 ng/mL 
(10.23–15.49 ng/mL) compared to 12.43 ng/mL (10.89–
14.38 ng/mL); p = 0.64 and p = 0.99, respectively). No 
differences were observed between 3- and 12-month 
measurements (p = 0.54). However, in patients without 
ECM fibrosis, galectin-3 levels significantly decreased 
between baseline and 3-month follow-up (14.61 ng/mL 
(11.46–17.47 ng/mL) compared to 12.58 ng/mL (10.23–
14.87  ng/mL); p  <  0.001). Although galectin-3 levels 
Fig. 2. 12-month patterns of serum galectin-3 in new-onset and chronic 
DCM
Fig. 3. 12-month patterns of serum galectin-3 in DCM with and without 
fibrosis
Fig. 5. Kaplan–Meier 12-month event-free curves for galectin-3 cut-off 
value of 14.54 ng/mL
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had a tendency to increase between 3- and 12-months, 
at  12-months the  levels still remained significantly 
lower in  comparison to  baseline values (14.61  ng/mL 
(11.46–17.47 ng/mL) compared to 13.44 ng/mL (10.28–
16.17 ng/mL); p < 0.05). The comparison of galectin-3 
levels between 3- and 12-months showed similar results 
(p = 0.15). Those patterns reveal that circulating galectin-3 
decreases in DCM patients without fibrosis; in patients 
with fibrosis, galectin-3 levels are unchanged. 
Galectin-3 and CV outcomes in DCM
During the 12-month follow-up, CV death occurred in 6 
(8.6%) patients and urgent HF hospitalization in 19 (27.1%) 
patients. Thus, the combined endpoint occurred in 25 pa-
tients. Cox proportional hazard analyses revealed that base-
line galectin-3 was a predictor of CV death in unadjusted 
(hazard ratio (HR) = 1.204; 95% confidence interval (95% 
CI) = 1.024–1.415; p < 0.05) and adjusted (HR = 1.246; 95% 
CI = 1.02–1.523; p < 0.05) models. In addition, galectin-3 
was also a  significant predictor of  the combined end-
point in unadjusted (HR = 1.105; 95% CI = 1.012–1.207; 
p < 0.05) and adjusted (HR = 1.115; 95% CI = 1.009–1.231; 
p < 0.05) models. The ROC analysis was conducted to iden-
tify the optimal galectin-3 level for the prediction of CV 
death and the combined endpoint. The optimal galec-
tin-3 cut-off value for the prediction of CV death was 
18.592 ng/mL, with a sensitivity of 66.7% and specific-
ity of 84.4% (area under curve (AUC) = 0.74). Event rates 
were calculated using a Kaplan–Meier analysis according 
to the galectin-3 cut-off value determined with the ROC 
curve (Fig. 4). Patients with galectin-3 ≥18.592 ng/mL had 
a significantly increased risk of CV death (HR = 5.053; 
95% CI = 1.02–25.049; p < 0.05) compared to those with 
galectin-3 <18.592 ng/mL. The event curves are initially 
superimposed but begin to diverge after approx. 250 days. 
In terms of galectin-3 and the combined endpoint, the op-
timal cut-off value for galectin-3 was 14.54 ng/mL, with 
a sensitivity of 70.3% and specificity of 63% (AUC = 0.67). 
In  addition, event rates were calculated according 
Table 3. Correlations between galectin-3 and serum markers of fibrosis, measured at baseline and at 3- and 12-months follow-up





PICP [ng/mL] −0.08; 0.52 0.01; 0.92 0.07; 0.63
PINP [pg/mL] −0.06; 0.64 0.27; 0.03 0.17; 0.25
PIIICP [ng/mL] 0.27; 0.03 0.19; 0.13 0.29; 0.05
PIIINP [ng/mL] 0.12; 0.34 0.35; 0.006 0.13; 0.37
OPN [ng/mL] 0.27; 0.02 0.37; 0.004 0.35; 0.005
TGF-β1 [pg/mL] 0.17; 0.17 −0.08; 0.51 0.05; 0.97
CTGF [ng/mL] −0.09; 0.45 −0.04; 0.75 0.09; 0.53
MMP-2 [ng/mL] 0.27; 0.03 – –
MMP-9 [pg/mL] 0.05; 0.68 – –
TIMP-1 [pg/mL] 0.27; 0.03 – –
r – Spearman rho correlation coefficient; PICP – carboxy-terminal propeptide of procollagen type I; PINP – amino-terminal propeptide of procollagen 
type I; PIIICP – carboxy-terminal propeptide of procollagen type III; PIIINP – amino-terminal propeptide of procollagen type III; OPN – osteopontin; TGF-β1 
– transforming growth factor β1; CTGF – connective tissue growth factor; MMP-2 – matrix metalloproteinase-2; MMP-9 – matrix metalloproteinase-9; TIMP-1 
– tissue inhibitor-1.
Table 4. Levels of galectin-3 at baseline and at 3- and 12-month follow-up in patients with new-onset and chronic DCM
Parameter New-onset DCM (n = 35) Chronic DCM (n = 35) p-value 
Baseline galectin-3 [ng/mL] 14.01 (11.17–17.8) 14.54 (11.04–16.39) 0.79
3-month galectin-3 [ng/mL] 12.42 (10.34–14.59) 12.66 (10.12–16.65) 0.53
12-month galectin-3 [ng/mL] 12.32 (10.22–15.26) 13.74 (10.43–16.59) 0.29
Data are presented as median and interquartile range; DCM – dilated cardiomyopathy.
Table 5. Levels of galectin-3 at baseline and at 3- and 12-month follow-up in DCM patients with and without ECM fibrosis
Parameter Fibrosis negative DCM (n = 46) Fibrosis positive (n = 24) p-value 
Baseline galectin-3 [ng/mL] 14.61 (11.46–17.47) 12.9 (10.33–16.18) 0.29
3-month galectin-3 [ng/mL] 12.58 (10.23–14.87) 12.18 (10.23–15.49) 0.94
12-month galectin-3 [ng/mL] 13.44 (10.28–16.17) 12.43 (10.89–14.38) 0.53
Data are presented as median and interquartile range.
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to the galectin-3 cut-off of 14.54 ng/mL (Fig. 5). Patients 
with galectin-3  ≥14.54  ng/mL had a  significantly in-
creased risk of the combined endpoint (HR = 2.569; 95% 
CI = 1.098–6.009; p < 0.05) compare to those with ga-
lectin-3 <14.54 ng/mL. The event curves diverge quickly 
at approx. 50 days and continue to diverge with time.
Discussion
Relationships between galectin-3 and ECM 
fibrosis and serum markers of fibrosis
Based on numerous in vitro experiments, galectin-3 has 
been established as an important pro-fibrotic protein.4,5,16 
However, the question remains whether serum galectin-3 
level is associated with cardiac fibrosis and consequently 
can be used as a reliable biomarker. To date, investigators 
have reported contradictory findings. Following long-term 
LV assist device (LVAD) therapy, Lok et al. observed an in-
crease in myocardial fibrosis that paralleled an increase 
in the concentration of galectin-3. Although the authors 
did not perform robust statistical calculations on the as-
sociations between fibrosis and galectin-3, these find-
ings highlight their potential link.10 In contrast, Besler 
et al. observed relatively strong correlations (r = 0.63) 
between myocardial galectin-3 and biopsy-proven ECM 
fibrosis in inflammatory DCM. Importantly, the authors 
did not observe any relationship between serum galec-
tin-3 and fibrosis.17 Our study extends this negative find-
ing on the lack of association between ECM fibrosis and 
serum galectin-3 to non-inflammatory DCM (as no acute 
or chronic myocardial inflammation was observed in myo-
cardial samples).
The ECM fibrosis can also be assessed non-invasively 
by means of magnetic resonance imaging. Vergaro et al. 
observed that serum galectin-3 was an independent predic-
tor of LV fibrosis as assessed by LGE in DCM patients.11 
In a similar fashion, Lepojärvi et al. found that patients 
with stable coronary artery disease who had the highest 
values of plasma galectin-3 had the lowest post-LGE T1 
relaxation time, which was used as a non-invasive marker 
of cardiac fibrosis.18 There are both advantages and disad-
vantages to determining fibrosis via biopsy or resonance. 
Nevertheless, our study clearly demonstrated the absence 
of a relationship between biopsy-proven fibrosis and cir-
culating galectin-3.
Another approach used to  estimate cardiac fibrosis 
is  the measurement of  circulating markers of  fibrosis. 
However, this strategy should be interpreted with caution, 
as numerous studies have demonstrated the absence of as-
sociations between various markers of fibrosis and inva-
sively determined fibrosis.15,19–21 We report weak to moder-
ate correlations between baseline galectin-3 and markers 
of collagen synthesis such as PIIICP, OPN, MMP-2, and 
TIMP-1. Uniquely, we investigated associations between 
galectin-3 and markers of collagen synthesis, OPN, TGF, 
and CTGF at 3 and 12 months. In terms of markers of col-
lagen synthesis, the observed pattern is not consistent 
as we observed changing correlations between markers 
of collagen type I and III synthesis. On the other hand, for 
fibrosis controlling factors, the pattern is clear, as galec-
tin-3 repeatedly correlated with OPN.
Kinetics of galectin-3  
in dilated cardiomyopathy
Despite extensive exploration of galectin-3 in various 
cardiac conditions, the kinetics of galectin-3 have not been 
well-defined in patients with and without ECM fibrosis. 
As  suggested in a  recent American Heart Association 
(AHA) document, galectin-3 is a promising marker, but 
knowledge gaps – such as kinetic patterns – need to be 
addressed.22
Before any attempt is  made to  analyze the  kinetics 
of any circulating marker, it is of paramount importance 
to  understand its reference intervals, variability and 
biologic determinants. Krintus et al. have recently es-
tablished galectin-3 reference intervals based on a study 
of 180 healthy individuals. They reported the lack of im-
pact of known biological determinants, including age, 
on galectin-3 blood measurements.23 In terms of HF and 
galectin-3, it was reported that galectin-3 short-term 
biologic variability, defined as 5 measurements within 
a three-week period, was 7.1%, and long-term (3 measure-
ments within a three-month period) was 7.7%.24 Similar 
observations were made by Meijers et al.; there were low 
levels of biologic variability of galectin-3 in HF, in com-
parison to much higher variability of NT-proBNP, over 
a six-week period.25 In addition, we have previously re-
ported the 12-month kinetics of serum markers of col-
lagen synthesis, TGF and CTGF, which differ between 
patients with and without ECM fibrosis.26 In the present 
study, the kinetics of galectin-3 were analyzed over a lon-
ger 3- and 12-month follow-up, and the observed values 
significantly exceeded previously reported biological vari-
ability. In terms of galectin-3 in patients with ECM fibro-
sis, repeated measurements are within expected biologic 
variability. We identified 2 distinct patterns of galectin-3 
over a 12-month period. The 1st pattern was characterized 
by a gradual decrease and was observed in patients with 
a recent diagnosis of DCM and without ECM fibrosis. 
The 2nd pattern was characterized by stable measure-
ments and was observed in patients with chronic DCM 
and with ECM fibrosis.
Galectin-3 and outcomes  
in dilated cardiomyopathy
Despite numerous studies, the  relationship between 
circulating galectin-3 and CV outcomes has not been de-
finitively defined. Recently, professional cardiac societies 
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have suggested that galectin-3 is a potential new biomarker 
in the field of HF. However, the scientific evidence support-
ing the prognostic role of galectin-3 is weak and requires 
further evaluation. We  identified studies with contra-
dictory conclusions on the prognostic role of galectin-3 
in HF.27–36 Imran et al. have recently published a meta-
analysis of 13 studies that evaluated the prognostic role 
of galectin-3 in the context of NT-proBNP and parameters 
of renal function.37 The authors concluded that galectin-3 
was independently associated with CV mortality, both 
in HF and in the general population. In our study, we do 
not attempt to conclusively define the relationship of ga-
lectin-3 role in HF given study limitations such as a small 
sample size and a short observational period. However, 
we studied a homogenous mid-sized DCM cohort and 
used well-defined, clinical endpoints of CV mortality and 
the combined endpoint of CV mortality and urgent HF 
hospitalization. We observed that galectin-3 was clearly 
associated with predefined endpoints. Based on  ROC 
analyses, we were able to identify patients with a worse 
prognosis. Larger, well-designed studies are required to ul-
timately verify the prognostic role of galectin-3 before 
it can be included in diagnostic pathways.
Limitations
We  would like to  acknowledge several limitations 
of the study. The proper assessment of fibrosis may be 
influenced by sampling error, patchy distribution of fi-
brosis, and harvesting from right ventricle (RV) compared 
to LV. The MMP-2, MMP-9 and TIMP-1 were measured 
only at baseline. Our study population of 70 patients may 
seem small, and the observation period of 1 year may be 
relatively short. On the other hand, all of our patients un-
derwent biopsy, making the cohort at least a moderate-
size population in the field of DCM and biopsy studies. 
During the 12-month follow-up, we observed the occur-
rence of the primary endpoint in 25 patients (6 deaths and 
19 urgent hospital admissions), which constitutes a large 
number of events for analysis.
Conclusions
Circulating galectin-3 is unrelated to invasively-deter-
mined ECM fibrosis in DCM. Serial measurements of ga-
lectin-3 correlated with markers of  fibrosis, including 
markers of collagen synthesis and OPN. However, there 
were no correlations between galectin-3 and TGF or CTGF. 
Galectin-3 kinetics vary at 12 months in patients stratified 
according to disease duration and fibrosis status. Circu-
lating galectin-3 was independently associated with CV 
outcomes in DCM.
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